Axovant Plans Nelotanserin PhIII But Trial Endpoint Has Eyebrows Raised
Executive Summary
Axovant will move its 5HT2A receptor, nelotanserin, into Phase III studies later this year for Lewy body dementia patients, but the company is switching gears to focus on motor function over its previously stated target of visual hallucinations in patients.
You may also be interested in...
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.
Investing In People: Aligning VCs And Today’s Entrepreneurs
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Deals Of The Year 2019 Winners Announced
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
Need a specific report? 1000+ reports available
Buy Reports